BioNTech SE ADR [BNTX] stock prices are down -0.12% to $86.37 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BNTX shares have gain 1.97% over the last week, with a monthly amount drifted -2.34%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on May 14, 2024, when Evercore ISI initiated its In-line rating and assigned the stock a price target of $100. Previously, BMO Capital Markets started tracking the stock with Outperform rating on February 23, 2024, and set its price target to $127. On January 05, 2024, Oppenheimer initiated with a Perform rating. JP Morgan downgraded its rating to a Underweight and decreased its price target to $99 on December 01, 2023. HSBC Securities downgraded its rating to a Hold and reduced its price target to $111 on October 16, 2023. HSBC Securities started tracking with a Buy rating for this stock on July 14, 2023, and assigned it a price target of $124. In a note dated May 17, 2023, Redburn upgraded an Buy rating on this stock and boosted its target price from $165 to $170.
The stock price of BioNTech SE ADR [BNTX] has been fluctuating between $78.02 and $125.83 over the past year. Currently, Wall Street analysts expect the stock to reach $167.27 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $86.37 at the most recent close of the market. An investor can expect a potential return of 93.67% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
The BioNTech SE ADR [NASDAQ:BNTX] reported sales of 2.95B for trailing twelve months, representing a drop of -85.14%. Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is -0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 85.69 points at the first support level, and at 85.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 87.34, and for the 2nd resistance point, it is at 88.30.
Ratios To Look Out For
It’s worth pointing out that BioNTech SE ADR [NASDAQ:BNTX]’s Current Ratio is 11.38. Further, the Quick Ratio stands at 11.16, while the Cash Ratio is 5.59. Considering the valuation of this stock, the price to sales ratio is 6.96, the price to book ratio is 0.95 and price to earnings (TTM) ratio is 180.43.
